Stephen L. Rawlings

Array ( [id] => 17990192 [patent_doc_number] => 20220356229 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => Anti-Coronavirus Antibodies and Methods of Use [patent_app_type] => utility [patent_app_number] => 17/192243 [patent_app_country] => US [patent_app_date] => 2021-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 114968 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17192243 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17052237 [patent_doc_number] => 20210261671 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => FLT3 BINDING PROTEINS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/180435 [patent_app_country] => US [patent_app_date] => 2021-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37937 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 154 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17180435 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16962900 [patent_doc_number] => 20210214399 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-15 [patent_title] => PH LOW INSERTION PEPTIDE AND COMPOSITION THEREOF [patent_app_type] => utility [patent_app_number] => 17/171750 [patent_app_country] => US [patent_app_date] => 2021-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17294 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17171750 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16883737 [patent_doc_number] => 20210169932 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => CHIMERIC ANTIGEN RECEPTOR COMPRISING CO-STIMULATORY RECEPTOR AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/126966 [patent_app_country] => US [patent_app_date] => 2020-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4859 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17126966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16749962 [patent_doc_number] => 20210101971 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-08 [patent_title] => METHODS FOR TREATMENT OF CANCER COMPRISING TIGIT-BINDING AGENTS [patent_app_type] => utility [patent_app_number] => 17/119883 [patent_app_country] => US [patent_app_date] => 2020-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44071 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17119883 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16671316 [patent_doc_number] => 20210060079 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => CD19 SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/099608 [patent_app_country] => US [patent_app_date] => 2020-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11491 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17099608 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16671317 [patent_doc_number] => 20210060080 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => CD19 SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/099614 [patent_app_country] => US [patent_app_date] => 2020-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11508 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17099614 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16686775 [patent_doc_number] => 20210069250 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => NOVEL PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST HEAD AND NECK SQUAMOUS CELL CARCINOMA AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 17/076261 [patent_app_country] => US [patent_app_date] => 2020-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47468 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17076261 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16727900 [patent_doc_number] => 20210095047 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => PSMA Targeting Trispecific Proteins and Methods of Use [patent_app_type] => utility [patent_app_number] => 17/072370 [patent_app_country] => US [patent_app_date] => 2020-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15288 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17072370 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19354105 [patent_doc_number] => 12054534 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-06 [patent_title] => Prostate specific membrane antigen binding fibronectin type iii domains [patent_app_type] => utility [patent_app_number] => 16/949078 [patent_app_country] => US [patent_app_date] => 2020-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 23780 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16949078 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16870144 [patent_doc_number] => 20210163611 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN IL-4 RECEPTOR [patent_app_type] => utility [patent_app_number] => 17/064393 [patent_app_country] => US [patent_app_date] => 2020-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8297 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17064393 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16583090 [patent_doc_number] => 20210017492 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => USE OF RETINOIC ACID IN T-CELL MANUFACTURING [patent_app_type] => utility [patent_app_number] => 17/062170 [patent_app_country] => US [patent_app_date] => 2020-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18931 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17062170 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16748893 [patent_doc_number] => 20210100902 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-08 [patent_title] => PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING PROTEIN [patent_app_type] => utility [patent_app_number] => 17/030118 [patent_app_country] => US [patent_app_date] => 2020-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28267 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17030118 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16570682 [patent_doc_number] => 20210009688 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => ANTI-PD-1 ANTIBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/022719 [patent_app_country] => US [patent_app_date] => 2020-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8026 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17022719 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16589319 [patent_doc_number] => 10898561 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-26 [patent_title] => Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers [patent_app_type] => utility [patent_app_number] => 17/018695 [patent_app_country] => US [patent_app_date] => 2020-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 16 [patent_no_of_words] => 41617 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 154 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17018695 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16598118 [patent_doc_number] => 20210024649 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => Methods and Compositions for Antibody and Antibody-loaded Dendritic Cell Mediated Therapy [patent_app_type] => utility [patent_app_number] => 16/998734 [patent_app_country] => US [patent_app_date] => 2020-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37935 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16998734 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16946735 [patent_doc_number] => 20210205426 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions [patent_app_type] => utility [patent_app_number] => 16/989723 [patent_app_country] => US [patent_app_date] => 2020-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21174 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16989723 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16453994 [patent_doc_number] => 20200363420 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => ARTICLES AND METHODS DIRECTED TO PERSONALIZED THERAPY OF CANCER [patent_app_type] => utility [patent_app_number] => 16/983673 [patent_app_country] => US [patent_app_date] => 2020-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36208 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16983673 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16421949 [patent_doc_number] => 20200347147 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 16/937536 [patent_app_country] => US [patent_app_date] => 2020-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53732 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -57 [patent_words_short_claim] => 167 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16937536 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16468212 [patent_doc_number] => 20200369749 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-26 [patent_title] => IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS [patent_app_type] => utility [patent_app_number] => 16/920098 [patent_app_country] => US [patent_app_date] => 2020-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54333 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 131 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16920098 [rel_patent_id] =>[rel_patent_doc_number] =>)